Company Overview

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics, a technology that silences disease-causing genes at the messenger RNA level. The company operates primarily within the biotechnology and pharmaceutical industries, with a concentration on genetic, cardiometabolic, hepatic, and rare diseases. Alnylam’s revenue is driven mainly by product sales of its approved RNAi-based medicines and, to a lesser extent, collaboration and royalty revenue.

Founded in 2002, Alnylam was among the earliest companies to commercialize RNAi technology and has played a central role in establishing RNAi as a validated therapeutic modality. The company achieved a major milestone with the first-ever FDA approval of an RNAi therapeutic in 2018, marking its transition from a research-focused organization to a fully integrated commercial-stage biopharmaceutical company. Its strategic advantage lies in its proprietary RNAi delivery platforms and deep intellectual property portfolio, which underpin multiple approved therapies and a broad clinical pipeline.

Business Operations

Alnylam generates revenue primarily through its commercial therapeutics segment, which includes approved medicines for rare and cardiometabolic diseases, as well as through collaboration and royalty arrangements with large pharmaceutical partners. Key marketed products include therapies for hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria, all leveraging Alnylam’s RNAi platforms such as GalNAc conjugate delivery technology. Research and development activities remain central to operations, with substantial ongoing investment in clinical trials.

The company operates as a vertically integrated organization, encompassing discovery, clinical development, regulatory affairs, manufacturing oversight, and global commercialization. Alnylam maintains strategic alliances with major pharmaceutical companies, including longstanding partnerships with Regeneron Pharmaceuticals, Inc. and Roche Holding AG, which support late-stage development and commercialization in certain markets. Manufacturing is supported through a combination of internal capabilities and qualified third-party contract manufacturers.

Strategic Position & Investments

Alnylam’s strategy centers on expanding RNAi beyond rare diseases into large-population indications, particularly in cardiometabolic and cardiovascular diseases, while continuing to strengthen its leadership in genetic medicine. Growth initiatives include advancing late-stage clinical programs, pursuing label expansions for existing products, and investing in next-generation RNAi chemistries with improved durability and tissue targeting.

The company has made targeted investments and acquisitions to enhance its platform and pipeline, including the acquisition of Sirna Therapeutics (historical) and internal expansion of its discovery infrastructure. Alnylam also holds equity interests and collaboration rights in several partnered programs, allowing it to participate in upside from co-developed assets. Emerging areas of focus include hypertension, dyslipidemia, and complement-mediated diseases, reflecting a strategic shift toward broader commercial markets.

Geographic Footprint

Alnylam is headquartered in Cambridge, Massachusetts, United States, and operates globally with commercial, clinical, and corporate activities across North America, Europe, and parts of Asia-Pacific. The company has established regional headquarters in Europe to support regulatory, market access, and commercial operations, particularly for rare disease therapies.

Internationally, Alnylam’s products are marketed through a combination of direct commercial presence and strategic partnerships, enabling access to key healthcare markets while managing operational scale. Clinical development programs are conducted worldwide, supporting regulatory approvals and expanding the company’s influence across major pharmaceutical markets.

Leadership & Governance

Alnylam is led by an experienced executive team with deep expertise in biotechnology, drug development, and commercialization. The company’s leadership emphasizes scientific rigor, long-term innovation, and disciplined capital allocation to sustain growth as a leading RNAi therapeutics company.

Key executives include:

• Yvonne Greenstreet – Chief Executive Officer
• Kevin C. Josephson – Chief Financial Officer
• Pushkal Garg – Chief Research and Development Officer
• P. Kay Tye – Chief Legal Officer and General Counsel
• Tolga Tanguler – Chief Commercial Officer

The company was founded by Phillip A. Sharp, Paul Schimmel, David Bartel, and Phillip Zamore, whose academic work laid the scientific foundation for RNA interference and shaped Alnylam’s research-driven culture.